Despite posting strong operational growth and exceeding profit expectations, the telehealth provider Hims & Hers Health, Inc. is facing mounting pressure from legal investigations. The company’s shares have come under scrutiny as multiple law firms examine potential securities law violations, a situation compounded by a significant stock sale by its chief financial officer shortly after positive corporate news.
Law Firms Launch Parallel Investigations
The legal landscape for Hims & Hers is intensifying. Two separate firms have initiated probes into the company’s conduct. The Schall Law Firm has been examining since early February whether the company made misleading statements or failed to disclose material information to investors. Subsequently, on March 20, Kahn Swick & Foti announced its own investigation. This probe focuses on whether company officers or directors may have breached their fiduciary duties to shareholders.
CFO’s Well-Timed Stock Disposal
A transaction by a key executive has drawn particular attention. Chief Financial Officer Oluyemi Okupe sold 9,217 shares on March 20 at an average price of $23.77. The timing of these sales, worth approximately $220,000, is notable. They occurred just days after a share price rally triggered by a renewed distribution agreement with pharmaceutical giant Novo Nordisk. Okupe reduced his direct holding by 2.81%, effectively capitalizing on the elevated price level to exit a portion of his position.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Solid Fundamentals Contrast with Share Price Weakness
Operationally, the company recently presented a robust financial picture. For the last quarter, revenue climbed 28.4% year-over-year to nearly $618 million. Hims & Hers also surpassed analyst estimates for earnings per share, reporting $0.08. However, its revenue forecast for the first quarter of 2026 disappointed the market. In response, investment firm TD Cowen lowered its price target to $23 last week while maintaining a “Hold” rating. Consequently, the share price, which traded around $27 in early March, has slipped below the $20 mark.
All eyes are now on the upcoming earnings report scheduled for May 11, 2026. This release will provide investors with concrete details on the progress of the company’s shift away from its self-compounded GLP-1 medications. Furthermore, management will need to address whether the ongoing legal examinations are having any operational or financial impact on the current business year.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from March 31 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 31.
Hims & Hers: Buy or sell? Read more here...
